Inhalable indulin company MannKind has agreed to purchase Pfizer's Frankfurt-based insulin facility, including the relevant real property rights, the production equipment, a quantity of bulk insulin and a license to manufacture bulk insulin for use in pulmonary delivery. MannKind is handing over $33 million for the facility. The company says it plans to retain more than half of the current workforce. Release